Glaukos Corporation (GKOS)

Glaukos, headquartered in Aliso Viejo, California, is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for glaucoma, corneal disorders, and retinal diseases. Led by CEO Tom Burns, the company’s strategy is "The MIGS Pioneer"—leveraging its "Micro-Invasive Glaucoma Surgery" (iStent) technology to revolutionize eye care. Its core strategy centers on the "iDose TR" commercial launch and expanding its "Corneal Cross-Linking" portfolio. Glaukos’ mission is to transform the treatment of chronic eye diseases. The company is currently a high-growth leader in ophthalmology, utilizing its robust clinical pipeline and high-margin surgical devices to drive market share gains and address the massive unmet need for sustainable vision preservation therapies.